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Abstract
Until recently our knowledge of a genetic contribution to ovarian cancer focused almost exclusively on mutations
in the BRCA1/2 genes. However, through germline and tumor sequencing an understanding of the larger
phenomenon of homologous recombination deficiency (HRD) has emerged. HRD impairs normal DNA damage
repair which results in loss or duplication of chromosomal regions, termed genomic loss of heterozygosity (LOH).
The list of inherited mutations associated with ovarian cancer continues to grow with the literature currently
suggesting that up to one in four cases will have germline mutations, the majority of which result in HRD.
Furthermore, an additional 5–7% of ovarian cancer cases will have somatic HRD. In the near future, patients with
germline or somatic HRD will likely be candidates for a growing list of targeted therapies in addition to poly (ADP-
ribose) polymerase (PARP) inhibitors, and, as a result, establishing an infrastructure for widespread HRD testing is
imperative. The objective of this review article is to focus on the current germline and somatic contributors to
ovarian cancer and the state of both germline and somatic HRD testing. For now, germline and somatic tumor
testing provide important and non-overlapping clinical information. We will explore a proposed testing strategy
using somatic tumor testing as an initial triage whereby those patients found with somatic testing to have HRD
gene mutations are referred to genetics to determine if the mutation is germline. This strategy allows for rapid
access to genomic information that can guide targeted treatment decisions and reduce the burden on genetic
counselors, an often limited resource, who will only see patients with a positive somatic triage test.
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Background
Ovarian cancer is the fifth leading cause of death in women
in the United States with an estimated 22,280 new cases
and 14,240 deaths in 2016 [1]. The majority of women with
epithelial ovarian cancer (EOC) are diagnosed with ad-
vanced disease. Standard therapy includes surgical debulk-
ing and platinum and taxane-based chemotherapy,
resulting in complete clinical remission in up to 75% of pa-
tients, however only 30% of patients will be cured. Once
recurrent, ovarian cancer generally does not exhibit the
same level of chemo-sensitivity, highlighting the need for
rational therapies directed toward specific molecular
targets [2, 3]. The advent of next-generation sequencing
(NGS) has allowed for the systematic investigation of the
genomic and molecular alterations in EOC which can
identify patients as candidates for individualized targeted
therapy. EOC tumors with deficient homologous recom-
bination (HR) repair represent such a group and have
demonstrated sensitivity to poly(ADP-ribose)polymerase
(PARP) inhibitors [4–6]. The majority of homologous re-
combination deficient (HRD) tumors will occur in patients
with germline BRCA1 and BRCA2 mutations. However,
there also are patients with germline mutations in other
HR pathway genes and patients who do not carry an inher-
ited germline mutation but have tumors with sporadic
HRD mutations. Data from the Cancer Genome Atlas
(TCGA) demonstrates that approximately fifty percent of
high grade serous ovarian cancers have aberrations in HR
repair [7]. Patients and physicians now have access to NGS
analysis of both germline samples and somatic tumor
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tissue. The objective of this review article is to focus on the
current germline and somatic contributors to ovarian can-
cer and the state of germline and somatic HRD testing.
Homologous recombination (HR)
DNA damage is a constantly occurring phenomenon that
necessitates a complex network of molecular repair path-
ways in order to maintain genomic integrity and prevent
cell death. HR is an important pathway that allows repair
of double-stranded DNA breaks. HR operates during the
S and G2 phases of the cell cycle and relies on many pro-
teins including BRCA1 and BRCA2, proteins of the MNR
complex (MRE11/RAD50/NBS1), CtIP, MRE11, RAD51,
ATM, H2AX, PALB2, RPA, RAD52 and proteins of the
Fanconi anemia pathway [8, 9]. When cells have non-
functioning HR, for example due to BRCA1 or BRCA2
deficiency, they rely on other repair pathways like non-
homologous end-joining (NHEJ), which is less precise and
more error-prone [10]. NHEJ results in the accumulation
of additional mutations and chromosomal instability,
increasing the risk that a cell undergoes malignant trans-
formation [10, 11].
Until recently, hereditary EOC was thought to be caused
almost exclusively by mutations in BRCA1 and BRCA2,
with a small contribution from mutations in the DNA
mismatch repair (MMR) genes [12]. TCGA, however, has
shown that about half of high grade serous ovarian
cancers, the most common histologic subtype, have
aberrations in HR repair. Further investigation of the HR
pathway highlights multiple other protein co-factors that
are necessary for successful HR repair including RAD51C,
RAD51D, BRIP1, PALB2, BARD1 and the MMR genes
[12, 13]. This group of genes is collectively referred to as
the HRD genes [14].
Germline mutations in EOC
When considering the genetic contribution to carcino-
genesis, an important distinction is whether a mutation
is germline or somatic. Germline implies that the muta-
tion was inherited and is therefore present in all of the
individuals’ cells. Somatic mutations are those mutations
that are acquired and therefore occur exclusively in the
tumor cells. BRCA1 and BRCA2 are the most well-
known ovarian cancer susceptibility genes, with germline
genetic testing available since the 1990s [15]. BRCA
mutation-associated ovarian cancers have multiple
distinct clinical features including earlier age at diagno-
sis, visceral distribution of disease, improved survival,
enhanced sensitivity to platinum-based chemotherapies
and sensitivity to PARP inhibitors [16–18]. The preva-
lence of BRCA1/2 germline mutations in patients with
epithelial ovarian cancer is estimated to be about 11–
15% [19–21].
In June 2013 the Supreme Court ruled unanimously
against Myriad Genetics, invalidating the exclusive license
rights to BRCA1 and BRCA2 testing in the United States.
Following this decision, many other clinical laboratories
began offering BRCA1 and BRCA2 testing, both as single
gene tests and in the form of comprehensive genetic
panels [22]. Although used for many hereditary cancer
syndromes, multigene panels have been particularly inter-
esting in ovarian cancer. Recent literature suggests that up
to 24% of ovarian cancers are associated with germline
mutations, and of these, 29% have mutations in genes
other than BRCA1 or BRCA2 [12, 13, 23, 24] (Table 1).
Somatic mutations in EOC
Several publications have reported the presence of som-
atic BRCA1/2 mutations in ovarian cancer, highlighting
that both germline and somatic mutations in HRD genes
can result in ovarian cancer. TCGA sequenced 316 high
grade serous EOCs and matched germline patient DNA.
Germline BRCA1 mutations were discovered in 9% of
patients and BRCA2 mutations in 8%. Evaluation of
tumor tissue found additional somatic mutations in
BRCA1/2 (3%), EMSY (8%), PTEN (7%), RAD51C (3%),
ATM/ATR (2%) and Fanconi anemia genes (5%) [7].
Hennessy et al. [25] performed BRCA1 and BRCA2 se-
quencing of 235 unselected ovarian cancer tumors and
found mutations in 19% of cases (31 mutations in
BRCA1 and 13 in BRCA2). Germline DNA specimens
Table 1 Genes associated with hereditary ovarian cancer
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were available for 28 of the patients harboring a BRCA1
or BRCA2 tumor mutation. Eleven (39.3%) of the muta-
tions present in the EOC tumor were found to be som-
atic and 17 germline (60.7%) [25]. When evaluating 367
ovarian carcinomas, Pennington et al.[26] discovered
that 24% patients carried a germline mutations in HRD
genes and 9% of patients had a somatic tumor mutation.
Finally, Cunningham et al. [27] evaluated 279 EOC
patients and found that 3.5% of patients had somatic
mutations in BRCA1 (2.1%) and BRCA2 (1.4%). (Table 2).
The variable rates of somatic mutations reported in the
literature likely reflect differences in patient selection
(e.g., histologic subtype) and scope of testing (e.g.,
number of genes included on the NGS panel). Currently,
the true prevalence of somatic mutations remains un-
known, however it has been estimated as somewhere be-
tween 5 and 7% of cases. This implies that for every 4–5
ovarian cancer patients with a germline BRCA mutation
there will be one patient with a somatic mutation [8].
Genetic evaluation
Germline testing
Genetic testing for germline mutations is recommended
for all women with non-mucinous epithelial ovarian can-
cer by multiple professional societies including the Ameri-
can College of Medical Genetics and Genomics (ACMG)
[28], the American Society of Clinical Oncology (ASCO)
[29], the National Cancer Comprehensive Network
(NCCN) [30], the National Society of Genetic Counselors
(NSGC) [28] and the Society of Gynecologic Oncology
(SGO) [31]. Multigene panels can assess a virtually unlim-
ited number of genes in a method that is both time- and
cost-effective when compared to the prior standard of
single gene Sanger sequencing. The availability of NGS
technology combined with the Supreme Court ruling
invalidating exclusive gene patent rights has resulted in
rapid uptake of multigene panels [32]. The scope of avail-
able testing ranges from screening for founder mutations,
to sequencing BRCA1 and BRCA2, to full panel testing of
multiple cancer-associated genes.
Currently, the guidelines that recommend germline
testing do not make specific recommendations regarding
which of the many available platforms to utilize [14].
Cancer genetic counselors play an integral role both in
helping patients choose the specific method of testing
and analyzing the results, which are becoming increas-
ingly complex. While adding additional genes to panels
increases the chance of finding deleterious mutations it
also increases the likelihood of finding variants of uncer-
tain significance (VUS) and non-actionable mutations
defined as mutations for which the clinical relevance is
unclear and clinical management guidelines do not exist.
Finding VUS and non-actionable mutations does not im-
prove patient outcomes but can result in patient and
physician anxiety and unindicated and inappropriate in-
terventions [33]. Pre- and post-test cancer genetic coun-
seling has been recognized to benefit the individual
tested and relatives, associated with improved adherence
to cancer risk management, better informed surgical
decision making, increased cancer genetics knowledge,
improved patient satisfaction and cost savings [34–46].
Discovering a germline mutation in a patient with
EOC has multiple significant clinical implications. As
previously stated, BRCA1/2-associated ovarian cancer
has multiple distinct features affecting age at diagnosis,
disease distribution, chemosensitivity and survival. Pa-
tients with known mutations have access to targeted
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therapy, for example PARP inhibitors for BRCA1/2 mu-
tation carriers. In December 2014, the U.S. Food and
Drug Administration (FDA) granted olaparib accelerated
approval for monotherapy in patients with germline
BRCA1/2 mutations and recurrent ovarian cancer with
three or more prior lines of chemotherapy, making
olaparib the first of the PARP inhibitors to receive FDA
approval. On December 19, 2016 the FDA granted accel-
erated approval to rucaparib in patients with recurrent
ovarian cancer with two or more prior lines of chemo-
therapy and either germline BRCA1/2 mutations or
somatic BRCA1/2 mutations in the tumor detected by a
next-generation sequencing-based companion diagnostic
test. The European Commission granted marketing
authorization for the PARP inhibitor olaparib as mono-
therapy in the maintenance treatment of adult patients
with platinum-sensitive, relapsed BRCA-mutated
(germline and/or somatic) high-grade serous epithelial
ovarian, fallopian tube, or primary peritoneal cancer who
are in complete response or partial response following
platinum-based chemotherapy [47]. The recently pub-
lished phase III data of Mirza et al. support the use of
Niraparib in the maintenance setting for patients with
platinum sensitive recurrent ovarian cancer. Patients
with germline HRD mutations derived the greatest clin-
ical benefit from this treatment [48].
In addition to treatment eligibility, many mutations
are predictive of other cancers in addition to ovarian
cancer, offering patients the opportunity for heightened
awareness and screening. Finally, identifying a germline
mutation can allow family members to undergo genetic
counseling and testing, termed “cascade” testing. In-
formed relatives have the opportunity to pursue inten-
sive cancer surveillance and risk-reducing options. Data
from individuals with Lynch syndrome demonstrate that
awareness of a mutation results in cancer prevention or
early diagnosis of cancer, which can improve morbidity
and prevent mortality [49–51].
Tumor profiling
In addition to germline testing, multiple companies now
offer tumor genetic profiling for somatic mutations.
There are methods using NGS similar to that done for
germline DNA. There are also independent DNA-based
measures of genomic instability reflecting underlying
tumor HRD on the basis of loss of heterozygosity
(LOH), telomeric allelic imbalance (TAI) and large-scale
state transitions (LST). Each individual metric and the
combination is significantly associated with BRCA1/2
status and identifying HRD tumors [52–54]. Somatic
mutation testing is more laborious and less reproducible
than germline testing for several reasons. First, unlike
germline testing, somatic testing utilizes a heterogeneous
collection of cells. Different tumor types and specimens
will have varying quantities of normal cells and neoplas-
tic cells in a sample. Multiple methods of DNA evalu-
ation exist for tumor profiling. Obtaining high-quality
tumor DNA extraction relies on an adequately sized spe-
cimen that has been well preserved. In contrast to germ-
line testing which looks at DNA extracted from healthy
cells to determine if a mutation was inherited, somatic
testing evaluates the genetic composition of tumor cells.
Once adequate high-quality DNA has been obtained the
data analysis is also challenging. There is currently no
standard method of interpreting results. Laboratories
rely on databases such as COSMIC or in silico predictive
software to attempt to predict pathogenicity of findings
but neither is exhaustive [8]. Finally there is the issue of
the stability of a somatic mutation. Data suggest that
there is intra-tumor genetic heterogeneity resulting from
clonal evolution and the emergence of subclonal tumor
populations in high grade EOC, causing spatial and tem-
poral heterogeneity [55]. While data from the ARIEL-2
trial has begun to address this issue, demonstrating a
change in biomarker status over time, the phenomenon
of tumor heterogeneity is not fully understood [56].
Early evidence suggests that a somatic BRCA1/2 muta-
tion is a predictive biomarker of PARP inhibitor activity
however the number of patients with somatic mutations
that have been analyzed is low. In a phase II study of
olaparib, Gelmon et al. found that 24% of BRCA-negative
patients with high grade serous or undifferentiated ovarian
cancer achieved a radiological objective response [57]. In
the recent publication by Mirza et al. [48] niraparib main-
tenance therapy had activity in all patients with platinum
sensitive recurrent ovarian cancer, however there was im-
proved progression free survival in patients with germline
BRCA1/2 mutations and without germline BRCA1/2 mu-
tations but with HRD. Swisher et al. [59] found that for
patients with platinum sensitive recurrent ovarian cancer,
rucaparib had activity in patients with germline BRCA1/2
mutations and patients who were BRCA1/2 wild-type but
were found to be LOH high. LOH status was determined
by next-generation sequencing using a cutoff of 14% or
more of genomic LOH in pretreatment biopsy specimens
to be considered LOH high. Studies that are currently on-
going or recently completed, and future planned studies
will likely clarify this question, including SOLO-2
(NCT01874353) and ARIEL-3 (NCT01968213) [5, 60].
See Table 3 for a review of phase II/III trials of PARP in-
hibitors in ovarian cancer.
Somatic tumor testing has two important implications:
1) identifying patients for targeted therapies like PARP
inihibitors, 2) identifying patients who should be re-
ferred for genetic counseling and offered genetic testing.
Mutations that are purely somatic and not found in the
germline DNA are not inherited, cannot be passed to
offspring, and therefore do not warrant cascade genetic
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counseling and testing. If a patient is found to have a
mutation on tumor profiling, the only way to definitively
classify it as a germline versus somatic mutation is
through germline testing. As described previously,
Hennessy et al. [25] found that among 28 tumors with
BRCA1/2 mutations, 61% were the result of germline
inherited mutations. This presents an important ethical
consideration regarding patient counseling and informed
consent. Thorough genetic counseling and informed
consent are required prior to germline genetic testing
however this is not the case with tumor profiling. This is
important given that almost two-thirds of patients with
a mutation found on tumor profiling will have a germ-
line mutation which carries significant clinical implica-
tions for the patient and her family members.
Tumor profiling vs. germline testing?
It has become clear that both somatic and germline mu-
tation testing provide important information for patients
with EOC. The question is whether or not both are ne-
cessary and if so what is the ideal chronology of testing.
Table 4 outlines the advantages of each testing method.
Germline testing is more well established with more ro-
bust data linking results to valuable prognostic and pre-
dictive information. Germline testing can also identify
other cancers for which a patient is at risk and can initi-
ate cascade testing of family members. Somatic testing
will capture a larger number of patients with HRD who
can potentially receive targeted therapy and does not re-
quire access to a genetic counselor, which is limited in
many clinical settings.
This issue of genetic counseling as a limited resource
is an important one. The exponential growth in diagnos-
tic and treatment options that utilize genetic and
genomic sequencing information coupled with public
coverage of celebrity BRCA mutation status has led to
an increasing demand for genetic counselors [61, 62]. A
study of 3765 patients in the U.S. with epithelial ovarian
cancer found that only 50% of patients meeting
substantial-risk criteria for BRCA1/2 mutations were
referred to genetics [63]. Another study of 416 patients
in Ontario with epithelial ovarian cancer found that only
19% of patients had undergone clinical genetic testing
for BRCA1/2 [64]. There currently are not enough
genetic counselors and geneticists to meet this demand
and alternative service delivery models are being evaluat-
ing including telephone counseling, videoconferencing,
group counseling and direct-to-consumer testing [65].
Video-assisted genetic counseling has been found to
significantly increase the percentage of patients undergo-
ing testing compared to traditional referral to genetic
counseling (31% vs. 55%) however this method has not
yet been tested in a prospective manor [66].
The recent approval of rucaparib for BRCA positive
(germline or somatic) patients with recurrent ovarian can-
cer who have had two or more lines of therapy would
argue for tumor testing to screen for therapeutic options
and as a triage for germline testing. However, the success
of niraparib in significantly extending the duration of
progression-free survival in all platinum-sensitive recurrent
ovarian cancer patienrs, (those with and without BRCA1/2
mutations) indicates a great expansion of the population
who can benefit from PARP inhibitors. Interestingly Mirza
et al. even found efficacy in the non-germline BRCA muta-
tion and HRD-negative group (HR 0.58, P = 0.02). In an ex-
ploratory analysis of ARIEL2 Part 1, Swisher et al. [59]
found that among BRCA wild-type tumors, genomic LOH
was a more sensitive predictor of response than was muta-
tion of other HR genes and gene methylation. In the near
future PARP inhibitors may be available to all patients with
ovarian cancer regardless of their genetic profile for treat-
ment and maintenance therapy. With this expanded infor-
mation about germline mutations, somatic mutations and
LOH status may serve a new role, no longer as an indicator
Table 4 Advantages of germline versus somatic tumor testing
of HRD genes
Advantages of germline testing
1. Germline testing is a more well established technique.
DNA extraction is easier.
The results are highly accurate and reproducible.
2. Germline mutations have prognostic and predictive value.
There is robust data supporting the prognostic and predictive
value of germline BRCA1/2 mutations.
Such data is limited for somatic mutations.
3. Germline mutations can offer knowledge of risk for other
associated cancers.
As germline mutations often increase the risk for multiple cancers,
awareness of germline mutations allows patients to pursue risk-
reducing
interventions for other cancers.
4. Germline mutation identification is clinically relevant for family
members and allows for cascade testing.
Advantages of somatic testing
1. Somatic testing with NGS will identify a larger number of patients
with HRD who can be therapeutically targeted.
Including patients with somatic (and not germline) mutations who
would be missed with germline testing alone.
2. Somatic testing can help patients understand the magnitude of
clinical benefit from targeted therapy in the context of risks and
side effects of particular therapeutic agents.
3. Somatic testing does not require genetic counseling which is often
a limited resource.
4. Somatic testing can serve as a triage for germline testing.
Patients found to have a somatic mutation can then be referred to
clinical genetics for germline testing, allowing for better utilization
of genetic counselors and geneticists.
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of who is eligible for treatment with this class of drugs but
instead as a biomarker for treatment efficacy. This informa-
tion would allow individualized patient counseling where
the provider can offer information about the magnitude of
benefit given the patient’s genetic profile in the context of
risk of side effects.
In summary both somatic and germline testing offer
clinically important and not entirely overlapping infor-
mation. One strategy is to start with somatic tumor test-
ing and use this to triage additional testing. Those
patients found to have HRD gene mutations on somatic
testing can be referred to genetics to establish whether
the mutation is somatic or germline. This strategy would
allow for rapid access to genomic information that can
guide targeted treatment decisions especially with the re-
cent approval of rucaparib for BRCA mutation carriers,
and reduce the burden on genetic counselors who would
then only see patients with positive somatic testing.
Whether this proposed strategy is feasible based on
availability of testing resources and cost is unknown and
must be examined in future studies. Furthermore, given
recent niraparib data this strategy may not be needed as
therapeutic benefit was noted in the maintenance setting
in all patients with ovarian cancer regardless of BRCA or
HRD status.
Future directions, can somatic testing replace germline
testing?
Currently, as stated above, somatic tumor testing can pro-
vide information only about genetic aberrations in the
tumor, however as NGS continues to become increasing
widespread its applications will likely broaden. Stadler et
al. [67] recently published their experience with tumor
genomic profiling via NGS panels in 224 patients with
colorectal cancer. Previously in colorectal cancer NGS
panels were used to identify KRAS, NRAS and BRAF som-
atic mutations and parallel MMR protein assessment via
ether immunohistochemistry (IHC) or microsatellite in-
stability (MSI) analysis was used for initial screening of
Lynch syndrome. Mismatch repair deficiency (MMR-D)
occurs in 15–20% of colorectal tumors with one-quarter
resulting from Lynch syndrome [68]. Stadley and col-
leagues discovered that by utilizing an expanded NGS
panel with 341-genes, a specific mutational load cutoff
could reliably identify tumors with DNA MMR-D. This
was not surprising given that a deficiency in the DNA
MMR apparatus would be expected to result in more un-
corrected mismatched bases and thus a greater rate of
mutations. The authors concluded that the use of multi-
gene tumor panels may obviate the need for parallel
MMR protein assessment and thus make the molecular
work-up patients with colorectal cancer more efficient
and cost-effective. Identifying MMR-D is becoming par-
ticularly important as it may serve as a biomarker for
response to immunotherapy with checkpoint inhibitors in
colorectal and endometrial cancer [69, 70].
If somatic tumor profiling can replace MMR assessment,
the next question is whether or not somatic tumor profil-
ing can replace germline testing altogether. Currently none
of the tumor profiling platforms offer information on
germline mutational status however this may change. The
feasibility of this question was evaluated with a study com-
paring deep, uniform NGS sequencing of tumor tissue
compared to Clinical Laboratory Improvement Amend-
ments (CLIA)-certified, NGS-based germline exon sequen-
cing of 236-cancer related genes. A computational method
could predict the somatic status of mutations from tumor
tissue without the need for a matched normal control with
an accuracy of greater than 95%. As tumor profiling for
this indication is permitted under investigational use only
and is not CLIA-certified, the authors concluded that NGS
tumor sequencing can indicate which patients require add-
itional work-up for germline testing [71]. However, with
further analysis and certification, clinicians will likely be
able to use somatic testing to definitively predict germline
status. While this approach to testing may not make sense
for cancers with a low prevalence of hereditary causation,
it is very applicable and exciting in ovarian cancer where
up to a quarter of patients carry a germline mutation. The
FDA accelerated approvals of olaparib and rucaparib came
with specified companion diagnostic tests however there
are multiple available next-generation sequencing assays
and algorithms for defining LOH. Whether or not approval
for specific targeted therapies will mandate a specific
companion test and how physicians choose the most
appropriate diagnostic test remains unclear. Methods to
combine assays and validate data across the various PARP
inhibitors, so one cost-effective test can be utilized makes
logical sense.
Finally, an important remaining area of uncertainty is
the role of epigenetic alterations in EOC. HRD can result
from genomic processes that are distinct from germline
and somatic mutations in HR genes. For example BRCA1/
2 silencing can occur via indirect mechanisms including
promoter methylation and interactions with other pro-
teins involved in DNA repair. The clinical implications of
epigenetic changes remain unclear with conflicting data in
the literature. Chiang et al. [72] found that BRCA1 pro-
moter hypermethylation resulted in significantly shorter
survival when compared to BRCA1 germline mutations
and BRCA1 wild-type without promoter hypermethyla-
tion. In contrast, TCGA found no survival difference with
BRCA1 hypermethylation [7] and Cunningham et al. [27]
observed that BRCA1 methylated cases had a survival
benefit compared to germline wild-type and similar to that
of the germline mutation cases. Prospective studies are
necessary to better address the clinical significance of
epigenetic alterations in the HR pathway.
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Conclusions
It is clear that the knowledge of both germline and som-
atic mutation status is becoming increasingly important
in the management of patients with ovarian cancer. The
experience with PARP inhibitors in ovarian cancer clin-
ical trials demonstrates that the targeted therapeutic ef-
fect is beyond just BRCA germline mutations and more
widely applicable to HRD. Whether epigenetic modifica-
tions to HRD genes confer the same therapeutic sensitiv-
ity remains unclear however future studies will likely
allow for a better understanding of their underlying
mechanisms and clinical significance. The list of ovarian
cancer-associated genes continues to grow and the lit-
erature currently suggests that up to one in four women
with ovarian cancer will have a germline HR deficiency
and an additional 5–7% will have a somatic HR defi-
ciency. Currently, these patients with recurrent disease
are candidates for approved therapy with PARP inhibi-
tors, however in the near future there will likely be a
growing list of targeted therapies available for ovarian
cancer patients. As a result, infrastructure for wide-
spread somatic HRD testing in routine clinical practice,
as is the case for HER2 in breast cancer and epidermal
growth factor receptor in lung cancer, should be sup-
ported [8]. Furthermore, in the maintenance setting
where PARP inhibitors may be useful in all patients as
noted the NOVA trial, HRD testing maybe useful for
counseling to understand the magnitude of the benefit
in context with the risks of side effects. Both germline
and somatic tumor testing provide important and non-
overlapping clinical information. Further research is ne-
cessary to address whether somatic testing can com-
pletely replace germline testing or if the practice of
universal somatic tumor testing followed by directed
germline confirmation should be implemented.
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